Jeena Sikho Lifecare LimitedPharmaceuticals & HealthcareJSLL
Q1 FY27 concall · earnings callJeena Sikho Lifecare Limited
Jeena Sikho reported strong growth driven by its integrated preventive healthcare model, focusing on a 30% YoY revenue growth target and expansion into luxury wellness and OTC products.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations | ₹224 Cr | 29% YoY | |
| EBITDA | ₹92 Cr | 17% YoY | |
| PAT | ₹65 Cr | — | |
| EBITDA Margin | 41% | — | |
| PAT Margin | 28% | — | |
| Panchakarma Revenue Growth | 13% | YoY | |
| IPD Patient Growth | 33% | YoY | |
| Day Care Volume Growth | 31% | YoY |
TL;DR
- Revenue from operations grew 29% YoY to INR224 crores, with a 41% EBITDA margin.
- Management reiterated a target of INR3,000 crores turnover and 7,000-10,000 beds in 3-5 years.
- The product business grew 47% YoY, while service revenue grew 13%, impacted by a deliberate reduction in low-margin government business.
- A new ultra-luxury wellness center in Manali is set to open, targeting 35-40% EBITDA margins.
- Management advised judging performance on an annual, not quarterly, basis due to strategic investments and timing of marketing expenses.
Said on the call
“Preventing a disease before it occurs is far better than treating it after it arrives, and this forms the foundation of Jeena Sikho's philosophy.”
From the Q&A
| Topic | What management said |
|---|---|
| Flat QoQ Revenue and Segment Focus | Management defended flat QoQ service revenue by stating they deliberately reduced low-margin government business by two-thirds and emphasized judging growth year-on-year. They stated the strategy remains a 50-50 focus on products and services. |
| High Other Income | CFO clarified that INR14 crores other income included a one-time INR7 crores from warrant valuation and capital gain. Future other income is expected to be around INR4-5 crores per quarter. |
| Ultra-Luxury Wellness Projections | For the new Manali center, management projected Year 1: 50% occupancy, ADR of INR32,000-35,000, EBITDA margin of 35-40%. Year 2: 60% occupancy, ADR of INR35,000-37,000, with operating costs of only 9-10% due to a strategic lease deal. |
| One-Off Expenses in Q1 | Management identified incremental expenses: INR4 crores extra on advertisements booked for campaigns whose benefits will accrue later, INR2 crores for new software implementation, and ~INR50 lakhs for audit fees. |
| Volume vs Revenue Growth Disconnect | When asked why strong IPD (33%) and OPD (22%) volume growth translated to only 13% Panchakarma revenue growth, management cited the deliberate reduction in government business and a strategic decision to offer discounted rates to poorer patients to increase occupancy and doctor training ahead of Ayushman Yojana. |
| Bed Capacity and Expansion | Current operational bed count is 2,400 with 59% occupancy. Target for FY27 is 3,000 to 3,500 operational beds, with a long-term goal of 7,000-10,000 beds in 3-5 years. |
Guidance
- Targeting year-on-year growth of about 30%.
- Aiming for a turnover of INR3,000 crores in about 3 years, maximum before 5 years.
- Long-term target of INR1,000 crores PAT.
- Goal to reach 7,000 to 10,000 beds in the next 3 to 5 years.
- Expect to maintain EBITDA margin of 40% plus and net profit margin of 27% to 30%.
- Plans to launch three to four more luxury premium wellness centers across India.
Source
Summary written from the transcript filed by Jeena Sikho Lifecare Limited for the call held on 10 Aug 2026; published 18 Aug 2026, 20:27 IST.
More Q1 FY27 concalls ·How verification works ·Report an error